Clinical Trials Sponsored by Archimedes Development Ltd

Total 229 results

Archimedes Development Ltd

Completed

Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain

Cancers, Pain
Archimedes Development Ltd

Completed

Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

Cancers, Pain

United Kingdom
Archimedes Development Ltd

Unknown

Patient Satisfaction and Quality of Life Impact - PecFent® (Qualipec)

Breakthrough Cancer Pain

France
Archimedes Development Ltd

Unknown

Patient Satisfaction and Quality of Life Impact - PecFent® (Qualipec)

Breakthrough Cancer Pain

Spain
Archimedes Development Ltd

Completed

Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

Cancer Pain

United States
Calliditas Therapeutics AB
Archimedes Development Ltd

Completed

Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

IGA Nephropathy

Sweden
Futura Medical Developments Ltd.

Completed

Evaluating MED2005 & Nitrostat Bioavailability (FM58)

Erectile Dysfunction

United Kingdom
Futura Medical Developments Ltd.

Completed

Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

Erectile Dysfunction

United States, Bulgaria, Georgia, Poland
Futura Medical Developments Ltd.

Completed

Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction

Erectile Dysfunction

Latvia, Bulgaria, Czechia, Georgia, Hungary, Poland, Russian Federation, Slovakia, Ukraine
Kyowa Kirin Pharmaceutical Development Ltd

Active, not recruiting

Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

X-linked Hypophosphatemia (XLH)

Sweden, Spain, United Kingdom, Italy, Austria, France
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

Constipation, Signs and Symptoms, Digestive

United Kingdom, Denmark, Norway, Israel, Spain
Kyowa Kirin Pharmaceutical Development Ltd

Recruiting

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER) (PROSPER)

Mycosis Fungoides and Sézary Syndrome

Spain, United Kingdom, Netherlands, United States, Italy
Kyowa Kirin Pharmaceutical Development Ltd

Recruiting

A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth

X-Linked Hypophosphatemia

France, Netherlands, United Kingdom
Kyowa Kirin Pharmaceutical Development Ltd

Terminated

Naloxegol Health Outcome Post Authorisation Safety Study

Opioid Induced Constipation

Netherlands, United Kingdom
Kyowa Kirin Pharmaceutical Development Ltd

Completed

A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH

X-Linked Hypophosphataemia

United Kingdom
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH

X-linked Hypophosphatemia

United Kingdom, France, Ireland, Italy
Kyowa Kirin Pharmaceutical Development Ltd

Active, not recruiting

Registry for Patients With X-Linked Hypophosphatemia (XLH Registry)

X-Linked Hypophosphatemia

Spain, Italy, United Kingdom, France, Belgium, Denmark, Germany, Hungary, Portugal, Norway, Switzerland, Israel, Netherlands, Czechia, Bulgaria, Sweden, Slovenia, Ireland, Latvia, Slovakia
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Naloxegol Drug Utilization Post Authorisation Safety Study

Opioid Induced Constipation

United Kingdom, Norway, Sweden, Germany
Kyowa Kirin Pharmaceutical Development Ltd

Withdrawn

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years

Chemotherapy Induced Nausea and Vomiting
Kyowa Kirin Pharmaceutical Development Ltd

Withdrawn

Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years

Chemotherapy Induced Nausea and Vomiting
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

Chemotherapy Induced Nausea and Vomiting

United States
Galmed Research and Development, Ltd.

Suspended

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) (ARMOR)

Nonalcoholic Steatohepatitis (NASH)

United States
Galmed Research and Development, Ltd.

Enrolling by invitation

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Futura Medical Developments Ltd.
Parexel

Completed

Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model

Pain

United Kingdom
Ningbo Newbay Technology Development Co., Ltd

Recruiting

A Study of NB003 in Patients With Advanced Malignancies

Advanced Solid Tumor

United States, China, Korea, Republic of, Spain, France, United Kingdom
Anda Biopharmaceutical Development (Shenzhen) Co...

Recruiting

Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor

Pancreatic Tumor

China
NeoTX Therapeutics Ltd.
Translational Drug Development

Completed

Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NT-NAP-102-1)

Non-small Cell Lung Cancer

United States
Ningbo Newbay Technology Development Co., Ltd

Recruiting

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Sinovac Research and Development Co., Ltd.

Not yet recruiting

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infectious Disease

China
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults

COVID-19

China
Sinovac Research and Development Co., Ltd.

Active, not recruiting

Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose

COVID-19

Brazil
Sinovac Research and Development Co., Ltd.

Completed

Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic

COVID-19

Dominican Republic
Sinovac Research and Development Co., Ltd.

Suspended

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey

COVID-19

Turkey
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Mumps

China
Sinovac Research and Development Co., Ltd.

Completed

Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine

COVID-19 | Influenza

China
Sinovac Research and Development Co., Ltd.

Active, not recruiting

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents

COVID-19

Philippines, Malaysia, Chile, South Africa
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Immunogenicity of an Inactivated COVID-19 Vaccine

COVID-19

China
Sinovac Research and Development Co., Ltd.

Withdrawn

Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above

COVID-19
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults

Covid19

China
Overseas Pharmaceuticals, Ltd.
Beijing Capton Pharmaceutical Technology Development Co., LTD

Not yet recruiting

An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic（PK）Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects Under Fasting Conditions.

Epilepsy

China
Sinovac Research and Development Co., Ltd.

Recruiting

Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above

COVID-19

China
Sinovac Research and Development Co., Ltd.

Recruiting

Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

COVID-19

China
Sinovac Research and Development Co., Ltd.

Withdrawn

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong

COVID-19

China
Sinovac Research and Development Co., Ltd.

Suspended

Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine

COVID-19

China

3

Subscribe